title: Development of a new subclavian arterial infusion chemotherapy method for locally or recurrent advanced breast cancer using an implanted catheter-port system after redistribution of arterial tumor supply.
abstract: Locally or recurrent advanced breast cancers can receive arterial blood supply from various arteries, such as the internal thoracic artery (ITA), the lateral thoracic artery, and the other small arterial branches originating from the subclavian artery. Failure to catheterize and subsequent formation of collateral arterial blood supply from various arteries are some of the reasons why the response to conventional selective transarterial infusion chemotherapy is limited and variable. To overcome this problem, we developed a new subclavian arterial infusion chemotherapy method using an implanted catheter-port system after redistribution of arterial tumor blood supply by embolizing the ITA. We named this technique ("redistributed subclavian arterial infusion chemotherapy" (RESAIC)). Using RESAIC, patients can be treated on an outpatient basis for extended periods of time. Eleven patients underwent RESAIC, and the complete remission and partial response rate in 10 evaluable patients was 90%: complete remission [CR] n = 4, partial remission n = 4, stable disease n = 1, and not evaluable n = 1. Three of four patients with CR had no distant metastasis, and modified radical mastectomy was performed 1 month after conclusion of RESAIC. The resected specimens showed no residual cancer cells, and pathologically confirmed complete remission was diagnosed in each of these cases. Although temporary grade-3 myelosuppression was seen in three patients who were previously treated by systemic chemotherapy, there was no other drug-induced toxicity or procedure-related complications. RESAIC produced a better response and showed no major complications compared with other studies despite the advanced stage of the cancers.
authors.affiliation: Department of Radiology, St Marianna University School of Medicine, Sugao, Miyamae, Kawasaki, Kanagawa, Japan. taki-lrl@vy.catv.ne.jp
authors.forename: Kenji
authors.initials: K
authors.lastname: Takizawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shimamoto
authors.forename: Yukihisa
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Misako
authors.initials: M
authors.lastname: Yoshimatsu
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Yagihashi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Nakajima
authors.forename: Takashi
authors.initials: T
authors.lastname: Kitanosono
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015901:Angiography, Digital Subtraction; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003287:Contrast Media; D004621:Embolization, Therapeutic; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial / Q000295:instrumentation*; D008875:Middle Aged; D015641:Radiography, Interventional; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D015251:Epirubicin; D002945:Cisplatin; D005472:Fluorouracil